Regeneron and Sanofi's early payer engagement and below-market pricing for Dupixent led payers to celebrate, not criticize, the drug's price.

Regeneron priced Dupixent at less than half the average price of existing psoriasis drugs.

“We price our drug at less than half the price of the average psoriasis drugs just cuz we think it's the appropriate thing to do.”

Early and deep payer engagement by Regeneron and Sanofi ahead of dupilumab's launch resulted in payers celebrating the drug's price rather than criticizing it.

“The recent depixamab approval by the FDA the launch and the and the reception that the drug got from a pricing perspective is an extremely good example where Regeneron and Santa Fe spent time with the payers. They educated them with the PBMs and when the drug came to market they actually celebrated the price.”